You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 62 No. 10, October 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (22)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Similar articles in this journal
 Topic Collections
 •Alzheimer Disease
 •Behavioral Neurology
 •Prognosis/ Outcomes
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Delusions and Hallucinations Are Associated With Worse Outcome in Alzheimer Disease

Nikolaos Scarmeas, MD; Jason Brandt, PhD; Marilyn Albert, PhD; Georgios Hadjigeorgiou, MD; Alexandros Papadimitriou, MD; Bruno Dubois, MD; Maria Sarazin, MD; Davangere Devanand, MD; Lawrence Honig, MD, PhD; Karen Marder, MD, MPH; Karen Bell, MD; Domonick Wegesin, PhD; Deborah Blacker, MD, ScD; Yaakov Stern, PhD

Arch Neurol. 2005;62:1601-1608.

Background  Delusions and hallucinations are common in Alzheimer disease (AD) and there are conflicting reports regarding their ability to predict cognitive decline, functional decline, and institutionalization. According to all previous literature, they are not associated with mortality.

Objective  To examine whether the presence of delusions or hallucinations has predictive value for important outcomes in AD.

Design, Setting, and Participants  A total of 456 patients with AD at early stages (mean Folstein Mini-Mental State Examination [MMSE] score of 21 of 30 at entry) were recruited and followed up semiannually for up to 14 years (mean, 4.5 years) in 5 university-based AD centers in the United States and Europe. Using the Columbia University Scale for Psychopathology in AD (administered every 6 months, for a total of 3266 visit-assessments, average of 7.2 per patient), the presence of delusions and hallucinations was extracted and examined as time-dependent predictors in Cox models. The models controlled for cohort effect, recruitment center, informant status, sex, age, education, a comorbidity index, baseline cognitive and baseline functional performance, behavioral symptoms, and use of neuroleptics and cholinesterase inhibitors.

Main Outcome Measures  Cognitive (Columbia MMSE score of ≤20/57 [approximate Folstein MMSE score of ≤10/30]), functional (Blessed Dementia Rating Scale [parts I and II] score of ≥10), institutionalization equivalent index, and death.

Results  During the full course of follow-up, 38% of patients reached the cognitive, 41% the functional, 54% the institutionalization, and 49% the mortality end point. Delusions were noted for 34% of patients at baseline and 70% at any evaluation. Their presence was associated with increased risk for cognitive (risk ratio [RR], 1.50; 95% confidence interval [CI], 1.07-2.08) and functional decline (RR, 1.41; 95% CI, 1.02-1.94). Hallucinations were present in 7% of patients at initial visit and in 33% at any visit. Their presence was associated with increased risk for cognitive decline (RR, 1.62; 95% CI, 1.06-2.47), functional decline (RR, 2.25; 95% CI, 1.54-2.27), institutionalization (RR, 1.60; 95% CI, 1.13-2.28), and death (RR, 1.49; 95% CI, 1.03-2.14).

Conclusions  Delusions and hallucinations are very common in AD and predict cognitive and functional decline. Presence of hallucinations is also associated with institutionalization and mortality.


Author Affiliations: Cognitive Neuroscience Division of the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, the Gertrude H. Sergievsky Center, and the Departments of Neurology and Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY (Drs Scarmeas, Devanand, Honig, Marder, Bell, Wegesin and Stern); Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Md (Drs Brandt and Albert); Departments of Psychiatry and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (Dr Blacker); Department of Neurology, Hospital de la Salpetriere, Paris, France (Drs Dubois and Sarazin); and Department of Neurology, University of Thessaly, Larissa, Greece (Dr Papadimitriou).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTER

Delusions and Hallucinations in Alzheimer Disease
Sudeep S. Gill
Arch Neurol. 2006;63(4):627.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Caregiver-Recipient Closeness and Symptom Progression in Alzheimer Disease. The Cache County Dementia Progression Study
Norton et al.
J Gerontol B Psychol Sci Soc Sci 2009;64B:560-568.
ABSTRACT | FULL TEXT  

Physical Activity, Diet, and Risk of Alzheimer Disease
Scarmeas et al.
JAMA 2009;302:627-637.
ABSTRACT | FULL TEXT  

Seizures in Alzheimer Disease: Who, When, and How Common?
Scarmeas et al.
Arch Neurol 2009;66:992-997.
ABSTRACT | FULL TEXT  

Mediterranean Diet and Mild Cognitive Impairment
Scarmeas et al.
Arch Neurol 2009;66:216-225.
ABSTRACT | FULL TEXT  

Dementia of the Alzheimer Type
Jalbert et al.
Epidemiol Rev 2008;30:15-34.
ABSTRACT | FULL TEXT  

The Relation of Patient Dependence to Home Health Aide Use in Alzheimer's Disease
Scherer et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2008;63:1005-1009.
ABSTRACT | FULL TEXT  

Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease
Bruen et al.
Brain 2008;131:2455-2463.
ABSTRACT | FULL TEXT  

Race/ethnic differences in AD survival in US Alzheimer's Disease Centers
Mehta et al.
Neurology 2008;70:1163-1170.
ABSTRACT | FULL TEXT  

Disruptive Behavior as a Predictor in Alzheimer Disease
Scarmeas et al.
Arch Neurol 2007;64:1755-1761.
ABSTRACT | FULL TEXT  

Antipsychotic Drug Use and Mortality in Older Adults with Dementia
Gill et al.
ANN INTERN MED 2007;146:775-786.
ABSTRACT | FULL TEXT  

The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration
Ellul et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:233-239.
ABSTRACT | FULL TEXT  

Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia
Blaszczyk and Mathys
Journal of Pharmacy Practice 2007;20:13-28.
ABSTRACT  

Pharmacotherapy for behavioral and psychological symptoms of dementia in the elderly
Beier
Am J Health Syst Pharm 2007;64:S9-S17.
ABSTRACT | FULL TEXT  

Mediterranean Diet, Alzheimer Disease, and Vascular Mediation
Scarmeas et al.
Arch Neurol 2006;63:1709-1717.
ABSTRACT | FULL TEXT  

The progression of cognition, psychiatric symptoms, and functional abilities in dementia with lewy bodies and Alzheimer disease.
Stavitsky et al.
Arch Neurol 2006;63:1450-1456.
ABSTRACT | FULL TEXT  

Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease
Zhu et al.
Neurology 2006;67:998-1005.
ABSTRACT | FULL TEXT  

Delusions and hallucinations in Alzheimer disease.
Gill
Arch Neurol 2006;63:627-627.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.